← Back to Search

Educational Intervention for Prostate Cancer (IMPRINT Trial)

N/A

Recruiting

Led By Rana McKay, MD

Research Sponsored by University of California, San Diego

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

IMPRINT Trial Summary

This trialaims to increase prostate cancer patients' understanding of genetic testing to help them make informed decisions.

Who is the study for?

This trial is for men aged 18 or older who have been diagnosed with prostate cancer and meet the NCCN guidelines for germline testing. It's not open to those who've already had germline testing or have positive somatic genetic tests suggesting a possible inherited variant.Check my eligibility

What is being tested?

The study is examining the effectiveness of an educational session held in clinics aimed at increasing the rate of genetic testing among men with prostate cancer to identify inherited variants.See study design

What are the potential side effects?

Since this trial involves an educational intervention rather than medication, there are no direct medical side effects; however, participants may experience stress or anxiety related to learning about their genetic risk.

IMPRINT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Feasibility of a patient educational program to improve germline genetic testing for eligible patients with prostate cancer.

Malignant Neoplasms

Secondary outcome measures

Impact of germline testing results on prostate cancer management

Patient baseline attitudes towards germline testing and assess the impact of an education interventional on patient perceptions of germline testing

Patient baseline knowledge of germline testing and the change in knowledge of germline testing with the educational intervention.

+1 more

IMPRINT Trial Design

1Treatment groups

Experimental Treatment

Group I: Educational interventionExperimental Treatment1 Intervention

In-clinic or virtual educational session on germline testing in prostate cancer with a trained educator.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of California, San DiegoLead Sponsor

1,130 Previous Clinical Trials

1,552,809 Total Patients Enrolled

6 Trials studying Prostate Cancer

1,220 Patients Enrolled for Prostate Cancer

Rana McKay, MDPrincipal InvestigatorUCSD

Media Library

Educational intervention Clinical Trial Eligibility Overview. Trial Name: NCT05470036 — N/A

Prostate Cancer Research Study Groups: Educational intervention

Prostate Cancer Clinical Trial 2023: Educational intervention Highlights & Side Effects. Trial Name: NCT05470036 — N/A

Educational intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT05470036 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals have participated in this medical trial so far?

"Affirmative. The clinical trial data hosted on the website indicates that this medical study, which was originally posted on September 27th 2022, is actively searching for participants. Fifty individuals are needed from one particular site to complete enrollment requirements."

Answered by AI

Are there currently any available positions in this clinical trial?

"Patients are being sought for this trial, as clinicaltrials.gov details its postings from September 27th 2022 to November 2nd 2022."

Answered by AI

What are the primary aims of this research?

"The primary aim of this clinical trial, to be assessed over a one year period, is assessing the feasibility of an educational program as it relates to germline genetic testing in patients with prostate cancer. Secondary outcomes include ascertaining patient knowledge and attitudes towards such tests at baseline and post-intervention stages; lastly, evaluating the impact that these results have on overall management decisions for each individual case will also be examined through clinician surveys."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Improving Germline Testing in At-Risk Patients With Prostate Cancer

Rana Mckay 2022. "Improving Germline Testing in At-Risk Patients With Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05470036.

All > Prostate Cancer San Diego